Biogen's $5.6B Apellis Acquisition: New Therapies & Growth
Business & Finance News Today | 2 Min News | The Daily News Now! · The Daily News Now!
Audio is streamed directly from the publisher (api.fastcast.ai) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Biogens $5.6B Acquisition of Apellis: A Strategic Shift into Immunology and Rare Diseases
Biogen made headlines with its $5.6B acquisition of Apellis Pharmaceuticals, paying $41 per share in cash and offering a contingent value right for Apelliss key drugs. The deal brings two FDA-approved treatments to Biogens portfolio: Syfovre for eye conditions and Empaveli for rare blood and kidney disorders. Despite the broader markets positive response, Biogens stock dropped as investors questioned the deals immediate value. However, Biogens leadership views this as a strategic expansion into immunology and rare diseases, aligning with their push into new therapies like Alzheimers and postpartum depression for future revenue streams.
Support the show:
Get a discount at https://solipillow.com/discount/dnn.
Advertise on DNN:
[email protected]
This is an automated, high-level news summary based on public reporting.
Report issues to [email protected].
View sources & latest updates:
https://sources.thednn.ai/4a57366bcbd1c0cd